» Articles » PMID: 35992047

Development of Microneedle Patch Loaded with Solid Lipid Nanoparticles for the Effective Management of Parkinson's Disease

Abstract

The demand for drug delivery systems (DDS) to treat Parkinson's disease (PD) is still high, and microneedle (MN) assisted transdermal DDS offers enormous potential. Herbal products for PD have been shown to have antioxidant effects in reducing dopaminergic neurons from degeneration. Here, we attempted to incorporate solid lipid nanoparticles (SLNs) of into dissolvable microneedle arrays and evaluate its neuroprotective activity. The bloodless and painless microneedle arrays through the transdermal route deliver the drug across the blood-brain barrier at the desired concentration. The quality by design (QbD) approach was employed for optimizing the SLNs formulations. The mechanical strength, release studies, permeation investigation, skin irritation test, histopathological studies, biochemical studies, and behavioural tests SLNs loaded microneedle arrays were performed. The microneedle patches obtained were shown to be mechanically robust and were also found to be nonirritant with a decreased degree of bradykinesia, high motor coordination, and balance ability. Compared to systemic delivery systems, such an MN method can achieve a considerably lower effective dose and allow long-term home-based treatment.

Citing Articles

Lipid-based nanoparticles for drug delivery in Parkinson's disease.

Cai H, Liu D, Xue W, Ma L, Xie H, Ning K Transl Neurosci. 2024; 15(1):20220359.

PMID: 39654878 PMC: 11627081. DOI: 10.1515/tnsci-2022-0359.


Nanomedicine strategies for central nervous system (CNS) diseases.

Nagri S, Rice O, Chen Y Front Biomater Sci. 2024; 2.

PMID: 38938851 PMC: 11210682. DOI: 10.3389/fbiom.2023.1215384.


Retracted: Development of Microneedle Patch Loaded with Solid Lipid Nanoparticles for the Effective Management of Parkinson's Disease.

And Applications B Bioinorg Chem Appl. 2024; 2024:9852582.

PMID: 38298484 PMC: 10830303. DOI: 10.1155/2024/9852582.


Drug delivery for neurodegenerative diseases is a problem, but lipid nanocarriers could provide the answer.

Rajdoula Rafe M Nanotheranostics. 2024; 8(1):90-99.

PMID: 38164504 PMC: 10750117. DOI: 10.7150/ntno.88849.


Solid Lipid Nanoparticles Containing Dopamine and Grape Seed Extract: Freeze-Drying with Cryoprotection as a Formulation Strategy to Achieve Nasal Powders.

De Giglio E, Bakowsky U, Engelhardt K, Caponio A, La Pietra M, Cometa S Molecules. 2023; 28(23).

PMID: 38067437 PMC: 10707881. DOI: 10.3390/molecules28237706.


References
1.
Hayes M . Parkinson's Disease and Parkinsonism. Am J Med. 2019; 132(7):802-807. DOI: 10.1016/j.amjmed.2019.03.001. View

2.
Kumar R, Kumar R, Khurana N, Singh S, Khurana S, Verma S . Enhanced oral bioavailability and neuroprotective effect of fisetin through its SNEDDS against rotenone-induced Parkinson's disease rat model. Food Chem Toxicol. 2020; 144:111590. DOI: 10.1016/j.fct.2020.111590. View

3.
Kaur I, Bhandari R, Bhandari S, Kakkar V . Potential of solid lipid nanoparticles in brain targeting. J Control Release. 2008; 127(2):97-109. DOI: 10.1016/j.jconrel.2007.12.018. View

4.
Roodenrys S, Booth D, Bulzomi S, Phipps A, Micallef C, Smoker J . Chronic effects of Brahmi (Bacopa monnieri) on human memory. Neuropsychopharmacology. 2002; 27(2):279-81. DOI: 10.1016/S0893-133X(01)00419-5. View

5.
de Bie R, Clarke C, Espay A, Fox S, Lang A . Initiation of pharmacological therapy in Parkinson's disease: when, why, and how. Lancet Neurol. 2020; 19(5):452-461. DOI: 10.1016/S1474-4422(20)30036-3. View